CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net income (loss)	$ 872,132	$ (199,426)	$ (278,017)
Less: Net income from discontinued operations	(964,956)	(65,645)	(16,806)
Net loss from continuing operations	(92,824)	(265,071)	(294,823)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	3,716	4,802	4,707
Amortization and accretion income, net	(681)	10	(1,079)
Ampreloxetine interest accretion	974
Share-based compensation	39,734	62,061	62,976
(Gain) loss on disposal of property and equipment	(8)	39
Gain on sale of Velusetrag	(2,709)
Amortization of right-of-use assets	3,989	3,786	3,344
Gain from lease modification		(1,863)
Loss on extinguishment of debt	3,034
Other		10	(95)
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	(2,720)	1,803	6,128
Prepaid clinical and development services	8,733	10,129	(17,638)
Other prepaid and current assets	(704)	2,867	(2,327)
Right-of-use lease assets	(4,424)
Other assets	(3,802)	(972)	(1,110)
Accounts payable	(1,612)	(3,534)	3,658
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(14,086)	(37,225)	5,983
Accrued interest payable	(1,246)
Deferred revenue	(192)	(11,463)	(26,465)
Operating lease liabilities	(1,024)	(1,742)	1,600
Unrecognized tax benefits	63,952	(189)	(8,542)
Other long-term liabilities	(525)	777	936
Net cash used in operating activities - continuing operations	(2,425)	(235,775)	(262,747)
Net cash (used in) provided by operating activities - discontinued operations	(184,566)	27,917	12,344
Net cash used in operating activities	(186,991)	(207,858)	(250,403)
Investing activities
Purchases of property and equipment	(572)	(3,406)	(6,616)
Purchases of marketable securities	(103,145)	(158,305)	(401,987)
Maturities of marketable securities	158,000	286,199	399,318
Sale of short-term investments and marketable securities	17		19,942
Proceeds from the sale of Velusetrag	2,709
Proceeds from the sale of property and equipment	1,866	6	64
Net cash provided by investing activities - continuing operations	58,875	124,494	10,721
Net cash provided by investing activities - discontinued operations	1,095,134
Net cash provided by investing activities	1,154,009	124,494	10,721
Financing activities
Ordinary share repurchases	(128,830)
Proceeds from the sale of ordinary shares, net		108,180	139,915
Proceeds from ampreloxetine funding, net	24,464
Proceed from issuance of 2035 notes			380,000
Proceeds from ESPP purchases	802	3,466	3,701
Proceeds from option exercises		5	1,361
Repurchase of shares to satisfy tax withholding	(3,450)	(9,061)	(9,749)
Net cash (used in) provided by financing activities - continuing operations	(738,617)	91,860	279,881
Net cash used in financing activities - discontinued operations	(20,189)		(16,796)
Net cash (used in) provided by financing activities	(758,806)	91,860	263,085
Net increase in cash, cash equivalents, and restricted cash	208,212	8,496	23,403
Cash, cash equivalents, and restricted cash at beginning of period	90,796	82,300	58,897
Cash, cash equivalents, and restricted cash at end of period	299,008	90,796	82,300
Supplemental disclosure of cash flow information
Cash paid for interest	22,244	39,029	24,024
Cash paid (received) for income taxes, net	117,966	(4,089)	14
2035 notes
Financing activities
Principal payment on notes	(399,998)	$ (10,730)	$ (235,347)
2033 notes
Financing activities
Principal payment on notes	$ (231,605)